Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee. Company Recommends Hemoglobin Target of 10-12 g/dL as Risk Management Approach.

This article is part of a special supplement published by Nephrology News & Issues in the February 2014 issue entitled, "Iron therapy and a quarter century of ESAs: What have we learned?"; The ...

A panelist highlights that after initial hemoglobin decline despite dose escalation, further increasing luspatercept dosing led to transfusion independence and hemoglobin improvement, underscoring the ...

Resistance to ESA therapy can occur in patients with malnutrition, folate or vitamin B 12 deficiency, secondary hyperparathyroidism, hemolysis, hemoglobinopathies, or primary bone marrow disorders ...

ESA doses during the 6 months before the inclusion of roxadustat were maintained at the level between 9000 and 12 000 IU/week (129.5 and 244.9 IU/kg/week). At the time of roxadustat therapy initiation ...

LOS ANGELES, March 30, 2017 /PRNewswire-iReach/ -- Therapy Pet has been operating in the animal assisted therapy niche for several years now. The organization focuses primarily on helping people ...